Oramed Pharmaceuticals
ORMP
56 hedge funds and large institutions have $18.6M invested in Oramed Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 17 reducing their positions, and 8 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
9% more capital invested
Capital invested by funds: $17M → $18.6M (+$1.57M)
1.95% more ownership
Funds ownership: 17.07% → 19.02% (+1.9%)
2% more funds holding
Funds holding: 55 → 56 (+1)
17% less call options, than puts
Call options by funds: $44K | Put options by funds: $53K
18% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$1.09M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$202K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$193K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$167K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$121K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$222K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$103K |
| 3 |
Two Sigma Investments
New York
|
-$74.4K |
| 4 |
Squarepoint
New York
|
-$68.7K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$60.3K |
ORMP Hedge Fund Activity: Q4 2024 in Review
56 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q4 2024, worth a combined $18.6M — up 9.2% from $17M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ORMP positions and 8 closed out — a net gain of 1 holder — while 14 added to existing stakes and 17 trimmed.
The largest buyer was BML Capital Management, adding an estimated $1.09M. The largest seller was Renaissance Technologies, cutting an estimated $222K.
- 56 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q4 2024, up from 55 in Q3 2024.
- Funds reported $18.6M of Oramed Pharmaceuticals stock for Q4 2024, up 9.2% quarter-over-quarter.
- 9 funds opened new Oramed Pharmaceuticals positions in Q4 2024 and 8 closed out, a net change of +1 holder.
- The largest Oramed Pharmaceuticals buyer in Q4 2024 was BML Capital Management, an estimated $1.09M added.
- The largest Oramed Pharmaceuticals seller in Q4 2024 was Renaissance Technologies, an estimated $222K sold.
Based on aggregated 13F filings for Q4 2024.